The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: A phase I, open-label, single dose-escalation study

Leukemia and Lymphoma

Volumn 54, Issue 4, 2013, Pages 708-713

  Vose, Julie M ^a   Friedberg, Jonathan W ^b   Waller, Edmund K ^c   Cheson, Bruce D ^d   Juvvigunta, Vasthala ^a   Fritsch, Holger ^e   Petit, Claude ^f   Munzert, Gerd ^e   Younes, Anas ^g  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c EMORY UNIVERSITY   (United States)

^d GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^f BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

BI 2536; Non Hodgkin lymphoma; Single dose escalation study

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; POLO LIKE KINASE 1;

ADULT; ADVERSE OUTCOME; ANEMIA; ARTICLE; CANCER RECURRENCE; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; CELL CYCLE PROTEINS; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PTERIDINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84877112319     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.729833     Document Type: Article

References (21)

1. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236.
2. Prichard M, Harris T, Williams ME, et al. Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma. Expert Opin Pharmacother 2009; 10: 983-995.
3. Johnston PB, Yuan R, Cavalli F, et al. Targeted therapy in lymphoma. J Hematol Oncol 2010; 3: 45.
4. Schoff ski P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 2009; 14: 559-570.
5. Golsteyn RM, Schultz SJ, Bartek J, et al. Cell cycle analysis and chromosomal localization of human Plk1, aputative homologue of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5. J Cell Sci 1994; 107: 1509-1517.
6. Golsteyn RM, Mundt KE, Fry AM, et al. Cell cycle regulation of the activity and subcellular localization of Plk1, ahuman protein kinase implicated in mitotic spindle function. J Cell Biol 1995; 129: 1617-1628.
7. Lake RJ, Jelinek WR. Cell cycle-and terminal diff erentiationassociated regulation of the mouse mRNA encoding a conserved mitotic protein kinase. Mol Cell Biol 1993; 13: 7793-7801.
8. Lee KS, Yuan YL, Kuriyama R, et al. Plk is an M-phase-specific protein kinase and interacts with a kinesin-like protein, CHO1/MKLP-1. Mol Cell Biol 1995; 15: 7143-7151.
9. Mito K, Kashima K, Kikuchi H, et al. Expression of polo-like kinase (PLK1) in non-Hodgkin's lymphomas. Leuk Lymphoma 2005; 46: 225-231.
10. Liu X, Erikson R L. P olo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 2003; 100: 5789-5794.
11. Steegmaier M, Hoff mann M, Baum A, et al. BI 2536, apotent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007; 17: 316-322.
12. Lenart P, Petronczki M, Steegmaier M, et al. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol 2007; 17: 304-315.
13. Mross K, Frost A, Steinbild S, et al. Phase I dose escalation and pharmacokinetic study of BI 2536, anovel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 2008; 26: 5511-5517.
14. Cheson BD, Horning SJ, Coiffi er B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
15. Soto E, Staab A, Freiwald M, et al. Prediction of neutropeniarelated Effects of a new combination therapy with the anticancer drugs BI 2536 (a Plk1 inhibitor) and pemetrexed. Clin Pharmacol Ther 2010; 88: 660-667.
16. Soto E, Staab A, Tillmann C, et al. Semi-mechanistic population pharmacokinetic/pharmacodynamic model for neutropenia following therapy with the Plk-1 inhibitor BI 2536 and its application in clinical development. Cancer Chemother Pharmacol 2010; 66: 785-795.
17. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology fi ndings and clinical outcomes. J Clin Oncol 2008; 26: 4124-4130.
18. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines □) . Non Hodgkin's lymphomas. Version 3. 2011. Available from: Http://www.nccn.org/ professionals/physician-gls/f-guidelines. asp
19. Jackson JR, Patrick DR, Dar MM, et al. Targeted anti-mitotic therapies: Can we improve on tubulin agents? Nat Rev Cancer 2007; 7: 107-117.
20. Friedberg J, Mahadevan D, Jung J, et al. Phase 2 trial of Alisertib (MLN8237), an investigational, potent inhibitor of aurora A kinase (AAK), in patients (pts) with aggressive B-and T-cell non-Hodgkin lymphoma (NHL). Blood 2011; 118(Suppl. 1): Abstract 95.
21. Rudolph D, Steegmaier M, Hoff mann M, et al. BI 6727, aPololike kinase inhibitor with improved pharmacokinetic profi le and broad antitumor activity. Clin Cancer Res 2009; 15: 3094-3102.